<DOC>
	<DOCNO>NCT00851877</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high-energy x-ray kill tumor cell . Paclitaxel albumin-stabilized nanoparticle formulation may make tumor cell sensitive radiation therapy . Giving radiation therapy paclitaxel albumin-stabilized nanoparticle formulation together cisplatin cetuximab may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose paclitaxel albumin-stabilized nanoparticle formulation give together cisplatin , cetuximab , radiation therapy see well work treat patient locally advanced stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation , Cisplatin , Cetuximab Given Together With Radiation Therapy Treating Patients With Locally Advanced Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose paclitaxel albumin-stabilized nanoparticle formulation combine cisplatin , cetuximab , radiotherapy patient local-regionally advance squamous cell carcinoma head neck . ( Phase I ) - To evaluate disease-free survival patient treat regimen . ( Phase II ) Secondary - To identify dose-limiting toxicity patient treat regimen . ( Phase I ) - To assess safety tolerability regimen . ( Phases I II ) - To assess progression-free survival survival patient treat regimen . ( Phase I ) - To assess overall survival patient treat regimen . ( Phase II ) - To assess response rate patient treated regimen . ( Phases I II ) OUTLINE : This multicenter , phase I dose-escalation study paclitaxel albumin-stabilized nanoparticle formulation follow phase II study . Patients receive cetuximab IV 120 minute week 1 . Patients receive cetuximab IV 60 minute , paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute , cisplatin IV 60 minute weekly week 2-8 . Patients also undergo 3D conformal intensity-modulated radiotherapy 30 minute day 1-5 week 2-8 . After completion study treatment , patient follow every 3 month 2 year every 6 month 4 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma oropharynx , hypopharynx , larynx Diagnosis base primary lesion and/or lymph node Stage III IV disease ( T2 , N23 , M0 T34 , N , M0 ) No primary tumor oral cavity , nasopharynx , sinus , salivary glands No distant metastasis chest xray , CT scan , PET/CT scan within past 6 week PATIENT CHARACTERISTICS : Zubrod performance status 01 ANC &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 9.0 g/dL ( transfusion intervention achieve hemoglobin &gt; 8.0 g/dL allow ) Bilirubin ≤ 1.5 mg/dL AST , ALT , AP ≤ 2.5 time upper limit normal Serum creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 50 mL/min None follow electrolyte abnormality grade 34 CTCAE v 3.0 : Calcium &lt; 7 mg/dL &gt; 12.5 mg/dL Glucose &lt; 40 mg/dL &gt; 250 mg/dL Magnesium &lt; 0.9 mg/dL &gt; 3 mg/dL Potassium &lt; 3 mmol/L &gt; 6 mmol/L Sodium &lt; 130 mmol/L &gt; 155 mmol/L Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior invasive malignancy , except nonmelanomatous skin cancer , unless diseasefree ≥ 3 year No prior allergic reaction study drug No active cardiac disease , define follow : Unstable angina Uncontrolled hypertension Myocardial infarction within past 6 month ( unless successfully treat coronary artery bypass graft percutaneous transluminal coronary angioplasty ) Uncontrolled arrhythmia Congestive heart failure Three heartrelated hospitalization within past year No severe chronic obstructive pulmonary disease require ≥ 3 hospitalization within past year No AIDS No preexist peripheral sensory neuropathy ≥ grade 2 No concurrent medical illness would impair patient tolerance therapy limit survival PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy cancer Prior systemic chemotherapy different cancer allow No prior radiotherapy region cancer would result overlap radiotherapy field No prior initial surgical treatment ( exclude diagnostic biopsy primary site nodal sample neck disease ) At least 48 hour since prior concurrent granulocytic growth factor ( e.g. , filgrastim [ GCSF ] ) radiotherapy No concurrent erythropoietic growth factor ( e.g. , darbepoetin , erythropoietin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>